ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
96,029.21
-0.11%
S&P 500
6,114.63
-0.01%
Dow Jones
44,546.08
-0.37%
US Dollar vs Yen
151.882
-0.30%
Brent Oil
74.81
0.77%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Aptose Biosciences Inc (APTO)

  7. Aptose Biosciences Inc (APTO) ニュース

APTO

Aptose Biosciences (APTO)

Aptose Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:APTO
日付受信時刻ニュースソース見出しコード企業名
2025/02/1506 : 57Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APTOAptose Biosciences Inc
2025/02/1410 : 26Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APTOAptose Biosciences Inc
2025/02/1407 : 30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APTOAptose Biosciences Inc
2025/02/1407 : 14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/02/1406 : 42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/02/1406 : 30GlobeNewswire Inc.Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market FacilityNASDAQ:APTOAptose Biosciences Inc
2025/02/1221 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/02/1221 : 00GlobeNewswire Inc.Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialNASDAQ:APTOAptose Biosciences Inc
2025/02/0406 : 46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/02/0406 : 41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APTOAptose Biosciences Inc
2025/01/2906 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/01/2207 : 21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/01/1322 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/01/1021 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2025/01/1006 : 00GlobeNewswire Inc.Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialNASDAQ:APTOAptose Biosciences Inc
2024/12/2006 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2024/12/2006 : 05GlobeNewswire Inc.Aptose Announces Positive Decision by Nasdaq Hearings PanelNASDAQ:APTOAptose Biosciences Inc
2024/12/1407 : 03Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:APTOAptose Biosciences Inc
2024/12/1300 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2024/12/1300 : 15GlobeNewswire Inc.Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with VenetoclaxNASDAQ:APTOAptose Biosciences Inc
2024/12/1002 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2024/12/1002 : 00GlobeNewswire Inc.Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLNASDAQ:APTOAptose Biosciences Inc
2024/12/0321 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2024/12/0321 : 30GlobeNewswire Inc.Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsNASDAQ:APTOAptose Biosciences Inc
2024/11/2708 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APTOAptose Biosciences Inc
2024/11/2606 : 27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2024/11/2606 : 15GlobeNewswire Inc.Aptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
2024/11/2520 : 05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APTOAptose Biosciences Inc
2024/11/2222 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
2024/11/2222 : 00GlobeNewswire Inc.Aptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:APTO

最近閲覧した銘柄

USOTC
DTEGY
Deutsche Telekom (QX)
COIN
XRPUSD
Ripple
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
NASDAQ
AAPL
Apple
NYSE
CVX
Chevron
AMEX
XLV
Health Care Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
SOLUSD
Solana
CCOM
US500
US 500
NYSE
XOM
Exxon Mobil
NASDAQ
AMZN
Amazon.com
USI
USTECH100
US Tech 100
NASDAQ
NVDA
NVIDIA
COIN
ADAUSD
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す